Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.

[1]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[2]  C. V. D. van de Velde,et al.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. , 1994, Cancer research.

[3]  R. Gertz,et al.  The significance of urokinase‐type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer , 1995, Cancer.

[4]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[5]  Y. Endo,et al.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. , 1998, British Journal of Cancer.

[6]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[7]  M. D. Di Marino,et al.  Expression of surface protein receptors in lung cancer. , 2002, Anticancer Research.

[8]  N. Brünner,et al.  High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage endometrial cancer , 2002, International journal of cancer.

[9]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[10]  N. Harbeck,et al.  Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. , 2004, Anticancer research.

[11]  M. Fujimura,et al.  Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. , 2005, Oncology reports.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  T. Eisen,et al.  Case‐control study of familial lung cancer risks in UK women , 2005 .

[14]  X. Shu,et al.  Functional Plasminogen Activator Inhibitor-1 Gene Variants and Breast Cancer Survival , 2006, Clinical Cancer Research.

[15]  K. Hemminki,et al.  PAI-1 −675 4G/5G polymorphism as a prognostic biomarker in breast cancer , 2008, Breast Cancer Research and Treatment.

[16]  K. Hemminki,et al.  Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Jemal,et al.  Global Cancer Statistics , 2011 .